909912-09-0Relevant articles and documents
PDIA4 INHIBITORS AND USE THEREOF FOR INHIBITING ?-CELL PATHOGENESIS AND TREATING DIABETES
-
Page/Page column 12, (2021/06/11)
Disulfide-Isomerase A4 (PDIA4) inhibitors and use thereof for inhibiting pancreatic β-cell pathogenesis and treating diabetes are disclosed. Drug candidates that inhibit PDIA4 with IC50 values ranging from 4 μM to 300 nM are identified. The compounds are highly active in augmenting insulin secretion from pancreatic β-cells. The representative compound No. 8 (4,5-dimethoxy-2-propiolamidobenzoic acid), alone or in combination with metformin, is effective in preserving pancreatic β-cell function, treating and/or reversing, returning blood glucose concentration to a normal level in a diabetic.
Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia
Helal, Christopher J.,Kang, Zhijun,Hou, Xinjun,Pandit, Jayvardhan,Chappie, Thomas A.,Humphrey, John M.,Marr, Eric S.,Fennell, Kimberly F.,Chenard, Lois K.,Fox, Carol,Schmidt, Christopher J.,Williams, Robert D.,Chapin, Douglas S.,Siuciak, Judith,Lebel, Lorraine,Menniti, Frank,Cianfrogna, Julia,Fonseca, Kari R.,Nelson, Frederick R.,O Connor, Rebecca,MacDougall, Mary,McDowell, Laura,Liras, Spiros
, p. 4536 - 4547 (2011/09/16)
Utilizing structure-based virtual library design and scoring, a novel chimeric series of phosphodiesterase 10A (PDE10A) inhibitors was discovered by synergizing binding site interactions and ADME properties of two chemotypes. Virtual libraries were docked and scored for potential binding ability, followed by visual inspection to prioritize analogs for parallel and directed synthesis. The process yielded highly potent and selective compounds such as 16. New X-ray cocrystal structures enabled rational design of substituents that resulted in the successful optimization of physical properties to produce in vivo activity and to modulate microsomal clearance and permeability.